Synopsis of recent research by authors named "Hsieng Sen Lu"
- Hsieng Sen Lu's research primarily focuses on the development and therapeutic applications of monoclonal antibodies, specifically in the context of migraine prevention.
- His notable work includes the discovery and approval of Aimovig (erenumab), which is the first FDA-approved antibody targeting a G-protein-coupled receptor, specifically the calcitonin gene-related peptide receptor (CGRP-R).
- The research emphasizes an innovative approach to therapeutic design, involving the creation of a novel, epitope-focused antigen to reconstruct stable extracellular domains of the CGRP-R, highlighting advancements in biopharmaceutical development.
